Colorectal Cancer

New York, NY

150 Colorectal Cancer Trials near New York, NY

Power is an online platform that helps thousands of Colorectal Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

PF-07799933 for Advanced Cancers

New York, New York
This trial tests a new medicine, PF-07799933, for people with advanced solid tumors that have a specific gene issue and haven't responded to other treatments. Participants will take PF-07799933 as a tablet regularly, and some may also take binimetinib or receive cetuximab shots. The goal is to see if these medicines are safe and effective.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:16+

156 Participants Needed

Autogene Cevumeran + Atezolizumab for Cancer

New York, New York
This trial tests a personalized cancer vaccine and an immune-boosting drug in cancer patients. The vaccine teaches the body to attack cancer, while the drug helps immune cells find and kill hidden cancer cells. This approach aims to induce strong anti-tumor responses by selecting suitable vaccines based on the patient's existing immune system.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

272 Participants Needed

LYT-200 + Chemotherapy/Tislelizumab for Cancer

New York, New York
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
No Placebo Group

Trial Details

Trial Status:Recruiting

80 Participants Needed

BCA101 + Pembrolizumab for Cancer

New York, New York
This trial is testing BCA101, a new drug that targets specific cancer growth proteins, in patients with advanced cancers that haven't responded to other treatments. The drug works by blocking proteins that help the cancer grow and spread.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

292 Participants Needed

TT-10 for Advanced Cancer

North Bergen, New Jersey
This trial tests a new oral drug, TT-10, for safety and effectiveness in people with severe cancers that did not improve with usual treatments. The goal is to determine a safe dosage and see if it can help control tumor growth.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

90 Participants Needed

A2B395 CAR T-Cell Therapy for Colorectal Cancer

New York, New York
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe for patients * Phase 2: Does the recommended dose of A2B395 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: * Enrollment in BASECAMP-1 (NCT04981119) * Preconditioning lymphodepletion (PCLD) regimen * A2B395 Tmod CAR T cells at the assigned dose
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

240 Participants Needed

A2B694 CAR T-Cells for Solid Cancers

New York, New York
This trial tests a new immune cell therapy for adults with difficult-to-treat solid tumors. The therapy modifies the patient's own immune cells to target and kill cancer cells while protecting healthy cells. The study aims to find a safe dose and see how well it works.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

230 Participants Needed

AZD5305 for Advanced Cancers

New York, New York
This trial is testing a new drug called AZD5305, which blocks a protein that helps cancer cells repair their DNA. It aims to see if the drug is safe and effective for patients with advanced solid tumors. By stopping the repair process, the drug hopes to kill cancer cells. AZD5305 has shown better tolerance in patients compared to earlier similar drugs.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

702 Participants Needed

NT-112 for Solid Tumors

New York, New York
This trial tests NT-112, a personalized immune cell treatment, in patients with advanced cancers that have a specific genetic mutation. The treatment boosts the patient's immune cells to target and kill cancer cells. This highly personalized cancer therapy involves giving the patient immune cells that directly attack cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

24 Participants Needed

PARG Inhibitor for Advanced Cancers

New York, New York
This trial is testing a new drug called IDE161 to see if it is safe and effective for patients with advanced cancers that have specific genetic changes. The drug works by preventing cancer cells from repairing their DNA, which can lead to their death.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

216 Participants Needed

Mobile Health Technology for Colorectal Cancer Recovery

New York, New York
This is a randomized clinical trial to evaluate the use of mobile devices in preventing readmission in patients undergoing major GI cancer operations.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

107 Participants Needed

Supportive Care for Young Adult Cancer Survivors

New York, New York
This trial studies how well an interactive survivorship program works in improving healthcare resources in adolescent and young adult cancer survivors. By improving access to survivorship resources, health literacy, self-management skills, and support, an interactive survivorship program may help to improve adherence to adolescent and young adult healthcare guidelines and reduce cancer-related distress.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

549 Participants Needed

CDX-585 for Cancer

New York, New York
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

130 Participants Needed

LY3537982 for Cancer

New York, New York
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

540 Participants Needed

[225Ac]Ac-AKY-1189 for Cancer

New York, New York
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

150 Participants Needed

BBO-11818 for KRAS Mutant Cancer

New York, New York
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

287 Participants Needed

FAPi Radioligand Therapy for Solid Cancers

New York, New York
This trial is testing two new drugs on patients with specific solid tumors that have high levels of a protein called FAP. The goal is to see if these drugs are safe and to find the best dose for future studies. The drugs work by targeting the FAP protein on the cancer cells.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

24 Participants Needed

TUB-030 for Cancer

New York, New York
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose. Participants will: Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

130 Participants Needed

ART0380 for Advanced Cancer

New York, New York
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

502 Participants Needed

LY4337713 for Cancer

New York, New York
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

241 Participants Needed

Why Other Patients Applied

"My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."

OF
Cholangiocarcinoma PatientAge: 54

"I had two chemotherapy regímens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this tríal. Thank you."

UM
Pancreatic Cancer PatientAge: 48

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."

FR
Lung Cancer PatientAge: 71

"I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."

EQ
Lung Cancer PatientAge: 70

NX-1607 for Advanced Cancer

New York, New York
This trial is testing NX-1607, a new experimental drug, in adults with advanced cancers that don't respond to standard treatments. The goal is to see if NX-1607 can safely stop or reduce cancer growth, either by itself or with another drug called paclitaxel. Paclitaxel is a widely used anti-cancer drug for treating various types of solid malignant tumors including breast, ovarian, and lung cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

345 Participants Needed

BMS-986340 + Nivolumab/Docetaxel for Cancer

New York, New York
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

949 Participants Needed

Entrectinib for Solid Tumors

New York, New York
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

534 Participants Needed

NGM831 + Pembrolizumab for Cancer

New York, New York
This trial is testing a new drug called NGM831 alone or with other drugs in patients with advanced or spreading solid tumors. The goal is to see if these treatments can help stop the cancer or help the immune system fight it better. One of the drugs being tested has been widely studied and used in various cancers, showing significant improvements in survival rates and being effective in combination with other treatments.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

130 Participants Needed

Targeted Therapy for Cancer

New York, New York
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

6452 Participants Needed

TRK-950 Combinations for Ovarian Cancer

New York, New York
This trial is testing a new drug, TRK-950, combined with other cancer treatments in patients with advanced cancers. The goal is to see if TRK-950 can help these treatments work better by boosting the body's ability to fight cancer or making cancer cells more vulnerable.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

138 Participants Needed

PC14586 for Solid Tumors

New York, New York
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12+

300 Participants Needed

BDTX-4933 for Cancer

New York, New York
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. However, the study may also proceed directly to the expansion phase. The study population for the Dose Expansion part of the study comprises adults with advanced/metastatic NSCLC with KRAS and/or BRAF mutations, and with Pancreatic Ductal AdenoCarcinoma (PDAC), ColoRectal Cancer (CRC), and Biliary Tract Cancer (BTC) with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations and alterations. All patients will self-administer S241656 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

554 Participants Needed

9-ING-41 for Advanced Cancers

New York, New York
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

350 Participants Needed

Brodalumab for Cancer Immunotherapy Side Effects

New York, New York
The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to closely mirror these autoimmune conditions. Brodalumab has not been approved by the United States Food and Drug Administration (FDA) for use in immunotherapy side effects but it has been approved for treatment of autoimmune conditions.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

11 Participants Needed

12345

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Colorectal Cancer clinical trials in New York, NY pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Colorectal Cancer clinical trials in New York, NY work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Colorectal Cancer trials in New York, NY 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in New York, NY for Colorectal Cancer is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in New York, NY several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Colorectal Cancer medical study in New York, NY?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Colorectal Cancer clinical trials in New York, NY?

Most recently, we added Screening Interventions for Early-Onset Colorectal Cancer, Botensilimab + Balstilimab for Colorectal Cancer and Meaning-Centered Therapy for Cancer to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in New York

Anxiety Clinical Trials in New York

Schizophrenia Clinical Trials in New York

ADHD Clinical Trials in New York

Bipolar Disorder Clinical Trials in New York

Multiple Sclerosis Clinical Trials in New York

Autism Clinical Trials in New York

Treatment Resistant Depression Clinical Trials in New York

Borderline Personality Disorder Clinical Trials in New York

Social Anxiety Disorder Clinical Trials in New York

Parkinson's Disease Clinical Trials in New York

Alzheimer's Disease Clinical Trials in New York

By Location

Clinical Trials near New York, NY

Clinical Trials near Rochester, NY

Clinical Trials near Bronx, NY

Clinical Trials near The Bronx, NY

Clinical Trials near Buffalo, NY

Clinical Trials near Brooklyn, NY

Clinical Trials near Syracuse, NY

Clinical Trials near Albany, NY

Clinical Trials near Stony Brook, NY

Clinical Trials near Manhasset, NY

Clinical Trials near New Hyde Park, NY

Clinical Trials near Mineola, NY

Other People Viewed

By Subject

Top Prostate Cancer Clinical Trials near New York, NY

Top Lung Cancer Clinical Trials near New York, NY

88 Breast Cancer Trials near New York, NY

15 Leiomyosarcoma Trials near New York, NY

21 Weight Loss Trials near New York, NY

24 Bipolar Disorder Trials near New York, NY

Top Depression Clinical Trials near New York, NY

Top Glioblastoma Clinical Trials near New York, NY

Top Depression Clinical Trials near New York City, NY

Top Clinical Trials near New York

Top Clinical Trials near New York

Top Clinical Trials near New Hyde Park, NY

By Trial

Colon Cancer Screening Toolkit for Colorectal Cancer

Single Port Robotic Surgery for Colorectal Cancer

HAIP Chemotherapy for Metastatic Colorectal Cancer

Time-Restricted Eating for Cancer · Recruiting Participants for Clinical Trial 2025 | Power | Power

Legal Support for Colorectal Cancer

LY3214996 + Cetuximab / Abemaciclib for Colorectal Cancer

Combination Immunotherapy for Human Papillomavirus & Colorectal Cancer

Fruquintinib + FOLFIRI for Colorectal Cancer

Drug Combination for Advanced Colorectal Cancer

Fecal Microbiota Transplant + Anti-PD-1 Therapy for Metastatic Colorectal Cancer

TATE + Pembrolizumab for Lung Cancer

Stereotactic Liver Ablation for Liver Cancer

Related Searches

Top Colorectal-cancer Clinical Trials near Ventura, CA

Top Colorectal-cancer Clinical Trials near Austin, TX

Top Hepatocellular-carcinoma Clinical Trials

Top Colorectal-cancer Clinical Trials near San Antonio, TX

Top Colorectal-cancer Clinical Trials near Chicago, IL

Top Colorectal-cancer Clinical Trials near Los Angeles, CA

Top Colorectal-cancer Clinical Trials near Baltimore, MD

Top Colorectal-cancer Clinical Trials near Columbia, SC

Top Colorectal-cancer Clinical Trials near Houston, TX

Top Colorectal-cancer Clinical Trials near Cincinnati, OH

Atovaquone for Ovarian Cancer

Selpercatinib + I-131 for Thyroid Cancer

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial